logo
Share SHARE
FONT-SIZE Plus   Neg

Watson Laboratories Files ANDA To Market Nebivolol Hydrochloride Tablets

Watson Laboratories Inc., a subsidiary of Watson Pharmaceuticals Inc. (WPI: Quote), has filed an Abbreviated New Drug Application with the FDA seeking approval to market Nebivolol Hydrochloride Tablets, the generic version of Forest Laboratories' Bystolic.

Bystolic is a beta-adrenergic blocking agent that is approved for the treatment of hypertension.

Forest Laboratories filed suit against Watson on March 13 in the US District Court of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent.

Watson said it might be the first applicant to file an ANDA for the generic version of Bystolic and if approved it will be entitled to 180 days of generic market exclusivity.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Uber Technologies Inc., the company behind the famous ride-sharing app, is expanding its pilot food delivery service program, UberEATS, to New York City and Chicago. Uber's new pilot program allows customers to order a meal that will be delivered to them within ten minutes. There is a $3 delivery... Standard Chartered said it is still reviewing whether to shift its headquarters out of London, at a time when banks in Britain face higher levy and regulatory costs. Tyson Foods Inc. (TSN) Tuesday said it plans to eliminate the use of human antibiotics from its chicken production, as the meat producing giant joins other peers who have taken similar steps in the wake of health concerns. Tyson Foods said it is striving to eliminate the use of antibiotics from its...
comments powered by Disqus
Follow RTT